John N. Kapoor
Founder at EJ Financial Enterprises, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Rao Akella | M | - |
EJ Financial Enterprises, Inc.
 EJ Financial Enterprises, Inc. SteelNon-Energy Minerals EJ Financial Enterprises, Inc. provides financial services. It offers advisory, mutual funds and startup investments services to the healthcare sector. The company was founded in 1990 and is headquartered in Lake Forest, IL. | - |
| Timothy R. Kelly | M | - |
EJ Financial Enterprises, Inc.
EJ Financial Enterprises, Inc. SteelNon-Energy Minerals EJ Financial Enterprises, Inc. provides financial services. It offers advisory, mutual funds and startup investments services to the healthcare sector. The company was founded in 1990 and is headquartered in Lake Forest, IL. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Steven J. Meyer | M | 67 |
Insys Pharma, Inc.
| 13 years |
| Patrick P. Fourteau | M | 77 |
Shionogi Pharma, Inc.
 Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 14 years |
| Brian Tambi | M | 78 |
Insys Pharma, Inc.
| 13 years |
| Andrew Long | M | 58 | 2 years | |
| Mahendra Shah | M | 79 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA.
EJ Financial Enterprises, Inc.
EJ Financial Enterprises, Inc. SteelNon-Energy Minerals EJ Financial Enterprises, Inc. provides financial services. It offers advisory, mutual funds and startup investments services to the healthcare sector. The company was founded in 1990 and is headquartered in Lake Forest, IL. | 12 years |
| Michael L. Babich | M | 47 |
Cordex Pharma, Inc.
 Cordex Pharma, Inc. Medical SpecialtiesHealth Technology Cordex Pharma, Inc. is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex Pharma was founded on February 9, 1996 and is headquartered in Philadelphia, PA. | 9 years |
| Rajat Rai | M | 57 |
Option Care, Inc. (Illinois)
 Option Care, Inc. (Illinois) Medical/Nursing ServicesHealth Services Option Care, Inc. provides specialty pharmacy and home infusion services. It services include home infusion, specialty pharmacy, ambulatory treatment, respiratory therapy, and home medical equipment. The company was founded in 1979 and is headquartered in Buffalo Grove, IL. | 26 years |
| Alan D. Weinstein | M | 81 | 11 years | |
| Laurence P. Birch | M | 64 |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 4 years |
| Franc E. Del Fosse | M | 52 | - | |
| Darrell Borne | M | 62 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | - |
| J. Enloe | M | 60 | - | |
| Saeed Motahari | M | 58 | 2 years | |
| Martin K. McCarthy | M | 65 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 5 years |
| William G. Campbell | M | - |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 5 years |
| Pierre LaPalme | M | 83 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 18 years |
| John R. Sabat | M | 73 | - | |
| Jonathan Kafer | M | 60 | - | |
| Sean Brynjelsen | M | 52 | 9 years | |
| Bruce Kutinsky | M | 58 | 9 years | |
| Shahid Ali | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 10 years |
| Paul Freiman | M | 89 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 years |
| Randall Pollard | M | 52 | - | |
| Charles E. Long | M | 85 | - | |
| Lawrence Kenyon | M | 58 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 6 years |
| Daniel Douglas von Hoff | M | 76 | - | |
| Kenneth S. Abramowitz | M | 73 | 10 years | |
| Joseph P. Bonaccorsi | M | 59 | - | |
| Rohit Vishnoi | M | 63 | - | |
| James W. Albrecht | M | 69 | - | |
| Acquilar Rahman | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 21 years |
| Ronald M. Johnson | M | 78 | 16 years | |
| Terry Rappuhn | F | 67 | 5 years | |
| Timothy A. Dick | M | 53 | 6 years | |
| Bernard A. Fox | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 years |
| Jerry N. Ellis | M | 86 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 10 years |
| Kerstin B. Menander | M | 87 | - | |
| Max W. Talbott | M | 76 | 6 years | |
| Andrece Housley | M | 56 | - | |
| Bala Venkataraman | M | 57 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 5 years |
| Guillermo A. Herrera | M | 70 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 2 years |
| Sanford J. Hillsberg | M | 75 |
Cordex Pharma, Inc.
Cordex Pharma, Inc. Medical SpecialtiesHealth Technology Cordex Pharma, Inc. is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex Pharma was founded on February 9, 1996 and is headquartered in Philadelphia, PA. | 7 years |
| Wilson Troutman | M | 69 | 8 years | |
| Adrienne Graves | M | 69 | 8 years | |
| Larry Dillaha | M | 60 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 8 years |
| Ronald E. Pauli | M | 63 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 1 years |
| Santosh Vetticaden | M | 65 | 2 years | |
| Craig Shular | M | 71 |
State University of New York at Buffalo
| 6 years |
| Darryl S. Baker | M | 55 | - | |
| Clivetty Martinez | M | - | - | |
| Joseph Poveromo | M | 77 |
State University of New York at Buffalo
| 1 years |
| Richard J. Ablin | M | - |
State University of New York at Buffalo
| 3 years |
| Tanri Abeng | M | 82 |
State University of New York at Buffalo
| 2 years |
| David A. Dooley | M | - |
State University of New York at Buffalo
| 4 years |
| Jennifer Bowles | F | - | - | |
| James Smeeding | M | - |
State University of New York at Buffalo
| 4 years |
| Ariyapadi N. Krishnaraj | M | - | - | |
| Ellen Feigal | M | 69 | 1 years | |
| Robert L. Kiehl | M | - |
State University of New York at Buffalo
| 3 years |
| John Mclaughlin | M | 76 |
State University of New York at Buffalo
| 4 years |
| Jaspreet Gill | F | - | 5 years | |
| Scott Grossenbach | M | - | 13 years | |
| Steve Sherman | M | - | 5 years | |
| Joe McGrath | M | - | 1 years | |
| Steven James | M | - | - | |
| Gregory P. Lawless | M | - | - | |
| Robert Monahan | M | - | 3 years | |
| Ted H. Stanley | M | 83 | 4 years | |
| David Sack | M | - |
State University of New York at Buffalo
| 4 years |
| Robert E. Sobol | M | 71 | 5 years | |
| Arjun C. Waney | M | - | - | |
| Martin J. Teitelbaum | M | 74 |
State University of New York at Buffalo
| 4 years |
| Jeffrey Whitnell | M | 68 | 5 years | |
| Richard H. Miller | M | - |
State University of New York at Buffalo
| 4 years |
| Arthur S. Przybyl | M | 67 | 7 years | |
| Rudolph Nisi | M | 92 |
Cordex Pharma, Inc.
Cordex Pharma, Inc. Medical SpecialtiesHealth Technology Cordex Pharma, Inc. is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex Pharma was founded on February 9, 1996 and is headquartered in Philadelphia, PA. | - |
| Subhash Vinayak Kapre | M | 76 | 3 years | |
| Randall James Wall | M | 65 | 3 years | |
| Steven J. Lichter | M | 65 | - | |
| Craig R. Smith | M | 77 |
State University of New York at Buffalo
| 3 years |
| William M. Steul | M | 81 |
State University of New York at Buffalo
| 2 years |
| Douglas P. Taylor | M | 76 |
State University of New York at Buffalo
| 4 years |
| Jerry I. Treppel | M | 69 | 6 years | |
| Richard Klenk | M | - |
State University of New York at Buffalo
| 4 years |
| Allan H. Cohen | M | 77 |
State University of New York at Buffalo
| 4 years |
| Abu S. Alam | M | 78 | - | |
| Neill Shanahan | M | - | - | |
| Richard D. Frederick | M | - |
State University of New York at Buffalo
| 3 years |
| Mark M. Silverberg | M | 69 | - | |
| Richard Mallery | M | 86 | - | |
| Duane Portwood | M | 57 | 6 years | |
| Christopher F. Homrich | M | - | - | |
| Mark Reynolds | M | 62 |
Cordex Pharma, Inc.
Cordex Pharma, Inc. Medical SpecialtiesHealth Technology Cordex Pharma, Inc. is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex Pharma was founded on February 9, 1996 and is headquartered in Philadelphia, PA. | 2 years |
| David M. Ascher | M | - |
State University of New York at Buffalo
| 4 years |
| Sam Boddapati | M | - | - | |
| Shawn Silvestri | M | - | - | |
| Thomas Allen Cole | M | 77 |
State University of New York at Buffalo
| 2 years |
| Matthew Thomas | M | - | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John N. Kapoor
- Personal Network
